Reports Q1 revenue EUR 182.8M vs. EUR 187.6M last year. “In the first quarter of 2025, we demonstrated continued execution against our strategic focus areas, highlighted by data updates for our PD-L1xVEGF-A bispecific antibody candidate BNT327 and the progress in clinical evaluation of our focus programs and combination treatment approaches,” said Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech (BNTX). “We will continue to focus on our key strategic programs as we remain steadfast in our vision to translate our science into survival for patients in need.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech names Ramon Zapata as CFO, succeeding Jens Holstein
- BNTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Trump Trade: RFK Jr. invests $500M in universal vaccine project
- RFK Jr. invests $500M in universal vaccine project, WSJ reports
- BioNTech SE: Promising Clinical Trials and Diversified Oncology Pipeline Support Buy Rating